Host: Rabbit

Target Protein: N4BP2L2/PFAAP5

IR: Immunogen Range:451-550/583

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 10443

Swiss Prot: Q92802

Source: KLH conjugated synthetic peptide derived from human N4BP2L2/PFAAP5:451-550/583 

Purification: affinity purified by Protein A

Storage: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Background: PFAAP5 is a 583 amino acid nuclear protein that potentially is involved in transcriptional regulation. PFAAP5 is phosphorylated on Ser 199 in response to DNA damage, probably by ATM or ATR. Primarily expressed in bone marrow, PFAAP5 is dramatically down-regulated after exposure to arsenic compounds, an event which precedes neutropenia. PFAAP5 interacts with both Gfi-1 and Neutrophil Elastase, two proteins that are implicated in neutropenia disorders. Defects in the gene encoding Neutrophil Elastase, ELA2, are the cause of cyclic haematopoiesis, which, with decreased numbers of circulating neutrophils, leads to an increased risk for opportunistic infection. Gfi1 is a transcriptional repressor that targets the ELA2 gene among others. With PFAAP5 expression, Neutrophil Elastase can potentiate repression of Gfi1 target genes, leading to the transcription of ELA2 and subsequent neutrophil differentiation. There are two isoforms of PFAAP5 that are produced as a result of alternative splicing events.